Company profile
BIAL - Portela
Privately-held (family-owned) pharmaceutical company
Privately held: no public share price · Portugal
Assets
(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Eslicarbazepine acetate(Aptiom) | Approved | Voltage-gated sodium channelSmall molecule | Epilepsy |
ZamicastatNo recent activity | Phase 2 | DBHSmall molecule | Hypertension |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.